References
- Piechaczek C. CD133. J Biol Regul Homeost Agents 2001; 15: 101–102.
- Green CL, Loken M, Buck D, Deeg HI Discordant expression ofAC133 and AC141 in patients with myelodysplastic syndrome (MDS) and acute myelogeneous leukemia (AML). Leukemia 2000; 14: 770–772.
- Massa M, Rosti V, Ramajoli I et al. Circulating CD34+, CD+, and vascular endothelial growth factor receptor2-positive endothelial progenitor cells in myelofibrosis with myeloid metaplasia. J Clin Oncol 2005; 23: 5688–5695.
- Buhring Hi, Seiffert M, Marxer A et al. AC133 antigen expressionis not restricted to acute myeloid leukemia blasts but is also found on acute lymphoid leukemia blasts and on a subset of CD34 + B-cell precursors. Blood 1999; 94: 832–833.
- Horn PA, Tesch H, Staib P et al. Expression of AC133, a novelhematopoietic precursor antigen, on acute myeloid leukemia cells. Blood 1999; 93: 1435–1437.
- Wuchter C, Ratei R, Spahn Get aL Impact of CD133 (AC133) andCD90 expression analysis for acute leukemia immunophenotyping. Haematologica 2001; 86: 154–161.
- Yin AH, Miraglia S, Zanjani ED et al. AC133, a novel marker forhuman hematopoietic stem and progenitor cells. Blood 1997; 90: 5002–5012.
- Yu Y, Flint A, Dvorin EL, Bischoff J. AC133-2, a novel isoform ofhuman AC133 stem cell antigen. J Biol Chem 2002; 277: 20711–206.
- Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. World Health Organization Classification of Tumours: pathology, and genetics of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press, 2001.
- Feller N, van der Pol MA, Waaijman T et al. Immunologic purging of autologous peripheral blood stem cell products based on CD34 and CD133 expression can be effectively and safely applied in half of the acute myeloid leukemia patients. Clin Cancer Res 2005; 11: 4793–4801.
- Cox CV, Evely RS, Goulden Ni, Blair A. Stem cells in T-ALL have a primitive CD133+ /CD34 +/CD7- phenotype. Blood (ASH Annu. Meet. Abstr.) 2004; 104: Abstract 1885
- Baldus CD, Radmacher M, Marcucci G et al. Co-expression of BAALC with ERG, TCF4, and CD133 indicates a shared pathway in acute myeloid and lymphoblastic leukemia. Blood (ASH Annu. Meet. Abstr.) 2005; 106: Abstract 2755
- Handgretinger R, Gordon PR, Leimig T et al. Biology and plasticity of CD133+ hematopoietic stem cells. Ann NY Acad Sci 2003; 996: 141–151.
- Barfield RC, Hale GA, Burnette K et al. Autologous transplanta-tion of CD133 selected hematopoietic progenitor cells for treat-ment of relapsed acute lymphoblastic leukemia. Pediatr Blood Cancer 2007; 48: 349–353.